EP Patent

EP3658156B1 — Telomerase inhibitor for use in treating a myelodysplastic syndrome

Assigned to Geron Corp · Expires 2026-03-25 · 0y expired

What this patent protects

Patent listed against imetelstat-sodium.

Drugs covered by this patent

imetelstat-sodium (IMETELSTAT SODIUM)

Patent Metadata

Patent number: EP3658156B1
Jurisdiction: EP
Classification: —
Expires: 2026-03-25
Drug substance claim: No
Drug product claim: No
Assignee: Geron Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.